Trademark Overview
On Friday, November 21, 2025, a trademark application was filed for NEXVOUND with the United States Patent and Trademark Office. The USPTO has given the NEXVOUND trademark a serial number of 99509699. The federal status of this trademark filing is NEW APPLICATION - RECORD INITIALIZED NOT ASSIGNED TO EXAMINER as of Friday, November 21, 2025. This trademark is owned by Eli Lilly and Company. The NEXVOUND trademark is filed in the Pharmaceutical Products category with the following description:
Pharmaceutical preparations, namely, pharmaceutical preparations for the treatment of alopecia, Alzheimer’s disease, atopic dermatitis, autoimmune diseases and disorders, blood diseases and disorders, bone and skeletal diseases and disorders, cancer, cardiovascular diseases, central nervous system diseases and disorders, cluster headaches, Covid-19 disease, Crohn’s disease, dementia, dermatological diseases and disorders, diabetes, dyslipidemia, endocrine diseases and disorders, fibromyalgia, gastrointestinal diseases and disorders, headaches, hearing loss, heart failure, inflammation and inflammatory diseases and disorders, inflammatory bowel disease, kidney diseases and disorders, liver diseases and disorders, lupus, mental disorders, metabolic diseases and disorders, migraines, multiple sclerosis, neurodegenerative diseases and disorders, neurological disorders, obesity, weight management, obstructive sleep apnea, osteoarthritis, pain, Parkinson’s disease, peripheral arterial ...
